Psoriasis | Treatment Algorithms: Claims Data Analysis | Pediatric Psoriasis | US | 2024

Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management of pediatric psoriasis is more challenging owing to the limited number of treatments approved for children. Only four biologics—Amgen’s Enbrel, Janssen’s Stelara, Eli Lilly’s Taltz, and Novartis’s Cosentyx—are approved to treat pediatric and adolescent patients with psoriasis. Although topical corticosteroids continue to be the mainstay of pediatric treatment, this class is expected to face competition from a nonsteroidal topical cream, Arcutis Biotherapeutics’ Zoryve, which recently received extended approval for patients 6 years of age or older. Additionally, the use of biologics is gradually increasing in pediatric patients, especially in the later lines, owing to the more-frequent and severe adverse events associated with long-term use of topical corticosteroids in children. Nevertheless, significant unmet need remains for efficacious therapies with better safety profiles for this psoriasis subpopulation.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric psoriasis? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric psoriasis patients?
• How have biologics such as Cosentyx, Enbrel, Humira, Stelara, and Skyrizi and the novel nonsteroidal topical Zoryve been integrated into the treatment algorithm? What are their sources of business?
• What percentage of pediatric psoriasis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of pediatric psoriasis patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States.

Real-world data: Longitudinal patient-level claims data analysis

Key drugs covered: Cosentyx, Elidel, Humira, Skyrizi, Stelara, Taclonex, Taltz, Zoryve

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.